IBIO
Price
$0.91
Change
-$0.08 (-8.08%)
Updated
Jun 5, 04:58 PM (EDT)
Capitalization
15.31M
REPL
Price
$9.74
Change
+$0.05 (+0.52%)
Updated
Jun 5, 04:59 PM (EDT)
Capitalization
751.6M
55 days until earnings call
Interact to see
Advertisement

IBIO vs REPL

Header iconIBIO vs REPL Comparison
Open Charts IBIO vs REPLBanner chart's image
iBio
Price$0.91
Change-$0.08 (-8.08%)
Volume$100
Capitalization15.31M
Replimune Group
Price$9.74
Change+$0.05 (+0.52%)
Volume$15.11K
Capitalization751.6M
IBIO vs REPL Comparison Chart
Loading...
IBIO
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
REPL
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
IBIO vs. REPL commentary
Jun 06, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is IBIO is a Hold and REPL is a StrongBuy.

Interact to see
Advertisement
COMPARISON
Comparison
Jun 06, 2025
Stock price -- (IBIO: $0.93 vs. REPL: $9.75)
Brand notoriety: IBIO and REPL are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: IBIO: 34% vs. REPL: 65%
Market capitalization -- IBIO: $15.31M vs. REPL: $751.6M
IBIO [@Biotechnology] is valued at $15.31M. REPL’s [@Biotechnology] market capitalization is $751.6M. The market cap for tickers in the [@Biotechnology] industry ranges from $323.27B to $0. The average market capitalization across the [@Biotechnology] industry is $2.31B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

IBIO’s FA Score shows that 1 FA rating(s) are green whileREPL’s FA Score has 1 green FA rating(s).

  • IBIO’s FA Score: 1 green, 4 red.
  • REPL’s FA Score: 1 green, 4 red.
According to our system of comparison, REPL is a better buy in the long-term than IBIO.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

IBIO’s TA Score shows that 3 TA indicator(s) are bullish while REPL’s TA Score has 8 bullish TA indicator(s).

  • IBIO’s TA Score: 3 bullish, 4 bearish.
  • REPL’s TA Score: 8 bullish, 2 bearish.
According to our system of comparison, REPL is a better buy in the short-term than IBIO.

Price Growth

IBIO (@Biotechnology) experienced а +18.54% price change this week, while REPL (@Biotechnology) price change was +4.06% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +7.85%. For the same industry, the average monthly price growth was +10.46%, and the average quarterly price growth was -0.86%.

Reported Earning Dates

IBIO is expected to report earnings on May 02, 2025.

REPL is expected to report earnings on Jul 31, 2025.

Industries' Descriptions

@Biotechnology (+7.85% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
REPL($752M) has a higher market cap than IBIO($15.3M). REPL YTD gains are higher at: -19.488 vs. IBIO (-62.184). IBIO has higher annual earnings (EBITDA): -15.11M vs. REPL (-216.51M). REPL has more cash in the bank: 537M vs. IBIO (4.96M). IBIO has less debt than REPL: IBIO (3.76M) vs REPL (76M). IBIO has higher revenues than REPL: IBIO (375K) vs REPL (0).
IBIOREPLIBIO / REPL
Capitalization15.3M752M2%
EBITDA-15.11M-216.51M7%
Gain YTD-62.184-19.488319%
P/E Ratio0.65N/A-
Revenue375K0-
Total Cash4.96M537M1%
Total Debt3.76M76M5%
FUNDAMENTALS RATINGS
IBIO vs REPL: Fundamental Ratings
IBIO
REPL
OUTLOOK RATING
1..100
116
VALUATION
overvalued / fair valued / undervalued
1..100
31
Undervalued
27
Undervalued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
9695
PRICE GROWTH RATING
1..100
9758
P/E GROWTH RATING
1..100
98100
SEASONALITY SCORE
1..100
50n/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

REPL's Valuation (27) in the Biotechnology industry is in the same range as IBIO (31). This means that REPL’s stock grew similarly to IBIO’s over the last 12 months.

REPL's Profit vs Risk Rating (100) in the Biotechnology industry is in the same range as IBIO (100). This means that REPL’s stock grew similarly to IBIO’s over the last 12 months.

REPL's SMR Rating (95) in the Biotechnology industry is in the same range as IBIO (96). This means that REPL’s stock grew similarly to IBIO’s over the last 12 months.

REPL's Price Growth Rating (58) in the Biotechnology industry is somewhat better than the same rating for IBIO (97). This means that REPL’s stock grew somewhat faster than IBIO’s over the last 12 months.

IBIO's P/E Growth Rating (98) in the Biotechnology industry is in the same range as REPL (100). This means that IBIO’s stock grew similarly to REPL’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
IBIOREPL
RSI
ODDS (%)
Bullish Trend 2 days ago
82%
Bullish Trend 2 days ago
90%
Stochastic
ODDS (%)
Bearish Trend 2 days ago
90%
Bearish Trend 2 days ago
90%
Momentum
ODDS (%)
Bullish Trend 2 days ago
79%
Bullish Trend 2 days ago
78%
MACD
ODDS (%)
N/A
Bullish Trend 2 days ago
74%
TrendWeek
ODDS (%)
Bullish Trend 2 days ago
81%
Bullish Trend 2 days ago
80%
TrendMonth
ODDS (%)
Bearish Trend 2 days ago
90%
Bearish Trend 2 days ago
85%
Advances
ODDS (%)
Bullish Trend 2 days ago
79%
Bullish Trend 2 days ago
77%
Declines
ODDS (%)
Bearish Trend 7 days ago
90%
Bearish Trend 23 days ago
85%
BollingerBands
ODDS (%)
Bearish Trend 2 days ago
90%
Bullish Trend 2 days ago
67%
Aroon
ODDS (%)
Bearish Trend 3 days ago
90%
Bullish Trend 2 days ago
81%
View a ticker or compare two or three
Interact to see
Advertisement
IBIO
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
REPL
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
THGIX26.000.03
+0.12%
Thornburg International Growth R6
SFECX22.88N/A
N/A
NAA Large Core C
USLIX73.92N/A
N/A
JHancock U.S. Global Leaders Growth I
LEQIX12.50N/A
N/A
LoCorr Dynamic Opportunity I
PRIKX14.99N/A
N/A
T. Rowe Price Real Assets I